



Figure S1 Consort diagram. *EGFR* M+, epidermal growth factor receptor mutation-positive; NSCLC, non-small cell lung cancer.

Table S1 Overall survival rate in four cohorts

Overall survival (%)	Cohort A (n=116)	Cohort B (n=143)	Cohort C (n=111)	Cohort D (n=367)	Total (n=737)	P*
12-month overall survival rate	98.3	98.2	84.8	88.7	91.4	0.001
24-month overall survival rate	89.8	81.8	64.3	82.0	80.3	
36-month overall survival rate	84.0	53.2	51.2	73.7	67.3	

*, chi-square test.

Table S2 Cumulative incidence of CNS failure during afatinib treatment

Cumulative incidence rate of CNS failure	No of patient who had brain metastasis at the time of initial diagnosis but no prior local treatment (n=131) (%)
12-month cumulative incidence rate of CNS failure	16.5%
24-month cumulative incidence rates of CNS failure	34.8%
36-month cumulative incidence rate of CNS failure	41.2%

CNS, central nervous system.